130 related articles for article (PubMed ID: 2846676)
1. C-peptide in non-alcoholic cirrhosis and hepatocellular carcinoma.
Pun KK; Ho PW; Yeung RT
J Endocrinol Invest; 1988 May; 11(5):337-43. PubMed ID: 2846676
[TBL] [Abstract][Full Text] [Related]
2. The use of glucagon challenge tests in the diagnostic evaluation of hypoglycemia due to hepatoma and insulinoma.
Pun KK; Young RT; Wang C; Tam CF; Ho PW
J Clin Endocrinol Metab; 1988 Sep; 67(3):546-50. PubMed ID: 2842361
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic beta-cell function in cirrhotic patients with and without overt diabetes. C-peptide response to glucagon and to meal.
Marchesini G; Melli A; Checchia GA; Mattioli L; Capelli M; Cassarani S; Zoli M; Pisi E
Metabolism; 1985 Aug; 34(8):695-701. PubMed ID: 3894876
[TBL] [Abstract][Full Text] [Related]
4. Studies of glucose intolerance in cirrhosis of the liver.
Shankar TP; Solomon SS; Duckworth WC; Himmelstein S; Gray S; Jerkins T; Bobal MA; Iyer RS
J Lab Clin Med; 1983 Oct; 102(4):459-69. PubMed ID: 6352838
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of insulin, C-peptide and glucagon in liver cirrhosis.
Gragnoli G; Signorini AM; Tanganelli I
J Endocrinol Invest; 1981; 4(1):1-5. PubMed ID: 7016966
[TBL] [Abstract][Full Text] [Related]
6. [Behavior of plasma insulin, C-peptide and glucagon in normal subjects and in patients with liver cirrhosis].
Gragnoli G; Tanganelli I; Signorini AM
Boll Soc Ital Biol Sper; 1980 Jan; 56(1):69-75. PubMed ID: 7002168
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of true insulin, C-peptide and proinsulin in peripheral blood of patients with cirrhosis.
Kasperska-Czyźykowa T; Heding LG; Czyzyk A
Diabetologia; 1983 Dec; 25(6):506-9. PubMed ID: 6363178
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance is the main determinant of impaired glucose tolerance in patients with liver cirrhosis.
Marchesini G; Bianchi GP; Forlani G; Rusticali AG; Patrono D; Capelli M; Zoli M; Vannini P; Pisi E
Dig Dis Sci; 1987 Oct; 32(10):1118-24. PubMed ID: 3308376
[TBL] [Abstract][Full Text] [Related]
9. Insulin, C-peptide and glucagon levels during OGTT in hepatic cirrhosis and in patients with prehepatic block.
Gerö L; Korányi L; Szalay F; Büki B; Tamás G
Acta Diabetol Lat; 1982; 19(1):55-64. PubMed ID: 7041501
[TBL] [Abstract][Full Text] [Related]
10. Insulin and C-peptide in ascitic fluid and plasma and their relative responses to glucagon in patients with cirrhosis.
Akgün S; Samanta A; Ertel NH
J Endocrinol Invest; 1988 Dec; 11(11):789-93. PubMed ID: 3066813
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic glucoregulatory hormones in cirrhosis of the liver: portal vein concentrations during intravenous glucose tolerance test and in response to a meal.
Holst JJ; Burcharth F; Kühl C
Diabete Metab; 1980 Jun; 6(2):117-27. PubMed ID: 6997101
[TBL] [Abstract][Full Text] [Related]
12. [Changes in carbohydrate metabolism in hepatic cirrhosis].
Conde Yagüe R; Gutiérrez-Cortines Corral MD; Ledesma Castaño F; González Coterillo T; Ortiz Ortiz M; Ramos Fernández R
Rev Clin Esp; 1985 Sep; 177(4):160-4. PubMed ID: 3906788
[No Abstract] [Full Text] [Related]
13. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study.
Mazziotti G; Sorvillo F; Morisco F; Carbone A; Rotondi M; Stornaiuolo G; Precone DF; Cioffi M; Gaeta GB; Caporaso N; Carella C
Cancer; 2002 Dec; 95(12):2539-45. PubMed ID: 12467068
[TBL] [Abstract][Full Text] [Related]
14. [Insulin and C-peptide in chronic liver diseases during oral glucose tolerance testing].
Oehler G; Knecht M; Bleyl H; Matthes KJ
Dtsch Med Wochenschr; 1984 Feb; 109(7):253-7. PubMed ID: 6365504
[TBL] [Abstract][Full Text] [Related]
15. Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis.
Petrides AS; Groop LC; Riely CA; DeFronzo RA
J Clin Invest; 1991 Aug; 88(2):561-70. PubMed ID: 1864966
[TBL] [Abstract][Full Text] [Related]
16. Glucose intolerance and hyperinsulinemia of cirrhosis are not results of spontaneous or surgical portosystemic shunting.
Sirinek KR; O'Dorisio TM; Levine BA
Am J Surg; 1991 Jan; 161(1):149-53. PubMed ID: 1987849
[TBL] [Abstract][Full Text] [Related]
17. Fasting hyperglycaemia following trans-catheter arterial chemo-embolization for hepatocellular carcinoma in cirrhosis.
Farinati F; Rinaldi M; Del Prato S; Lana S; De Maria N; Paleari D; Marafin C; Naccarato R
Ital J Gastroenterol Hepatol; 1997 Oct; 29(5):427-33. PubMed ID: 9494852
[TBL] [Abstract][Full Text] [Related]
18. Anomalous adenosine cyclic 3':5'-monophosphate responses to glucagon in patients with hepatocellular carcinoma.
Pun KK; Ho PW; Yeung RT
Cancer Res; 1986 Apr; 46(4 Pt 2):2152-4. PubMed ID: 3004721
[TBL] [Abstract][Full Text] [Related]
19. Insulin sensitivity and body composition in cirrhosis: changes after TIPS.
Holland-Fischer P; Nielsen MF; Vilstrup H; Tønner-Nielsen D; Mengel A; Schmitz O; Grønbaek H
Am J Physiol Gastrointest Liver Physiol; 2010 Aug; 299(2):G486-93. PubMed ID: 20489042
[TBL] [Abstract][Full Text] [Related]
20. Effects of spontaneous portal-systemic shunting on insulin metabolism.
Smith-Laing G; Sherlock S; Faber OK
Gastroenterology; 1979 Apr; 76(4):685-90. PubMed ID: 421995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
